HUP0401620A2 - Orális antidiabetikus hatóanyagok és eljárás előállításukra - Google Patents

Orális antidiabetikus hatóanyagok és eljárás előállításukra

Info

Publication number
HUP0401620A2
HUP0401620A2 HU0401620A HUP0401620A HUP0401620A2 HU P0401620 A2 HUP0401620 A2 HU P0401620A2 HU 0401620 A HU0401620 A HU 0401620A HU P0401620 A HUP0401620 A HU P0401620A HU P0401620 A2 HUP0401620 A2 HU P0401620A2
Authority
HU
Hungary
Prior art keywords
group
substituted
heteroaryl
hydrogen atom
aryl
Prior art date
Application number
HU0401620A
Other languages
English (en)
Inventor
Christopher Franklin Bigge
Alexander James Bridges
Agustin Casimiro-Garcia
Stephen Alan Fakhoury
Helen Tsenwhei Lee
Jessica Elizabeth Reed
Robert Philipp Schaum
Kevin Matthew Schlosser
Karen Elaine Sexton
Hairong Zhou
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of HUP0401620A2 publication Critical patent/HUP0401620A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)

Abstract

A találmány szerinti vegyületek (I) általános képletében A jelentésearilcsoport, szubsztituált arilcsoport, heteroarilcsoport,szubsztituált heteroarilcsoport, fuzionált heteroarilcsoport,szubsztituált fuzionált heteroarilcsoport, cikloalkilcsoport,szubsztituált cikloalkilcsoport, heterocikloalkilcsoport vagyszubsztituált heterocikloalkilcsoport, X jelentése 2-5-atomostérköztartó csoport, amely lehet (X-1), (X-2), (X-3), (X-4) vagy (X-5)képletű csoport, ahol a hullámos vonal a kapcsolódási pontot jelzi, Qjelentése arilcsoport, szubsztituált arilcsoport, heteroarilcsoport,szubsztituált heteroarilcsoport, fuzionált heteroarilcsoport vagyszubsztituált fuzionált heteroarilcsoport, azzal a megszorítással,hogy ha Q jelentése 5 tagú heteroarilcsoport, akkor az X csoport a Qcsoporthoz a heteroarilcsoport heteroatomjától eltérő atomon keresztülkapcsolódik, Y és Z jelentése egymástót függetlenül közvetlen kötésvagy (CR1R2)n és (CR3R4)m képletű csoport, ahol R1-R4 jelentéseegymástól függetlenül hidrogénatom, halogénatom, alkilcsoport,hidroxilcsoport vagy alkoxicsoport, n és m értéke egymástólfüggetlenül 1, 2 vagy 3, B jelentése hidrogénatom, halogénatom,alkilcsoport, halogénalkilcsoport vagy alkoxicsoport, D jelentésehidrogénatom, -NH-aril vagy -NH-(szubsztituált aril) képletű csoport,alkanoilcsoport, szubsztituált alkanoilcsoport, benzoilcsoport,szubsztituált benzoilcsoport, arilcsoport, szubsztituált arilcsoport,heteroarilcsoport, szubsztituált heteroarilcsoport, cikloalkilcsoport,szubsztituált cikloalkilcsoport, heterocikloalkilcsoport vagyszubsztituált heterocikloalkilcsoport, E jelentése COR5 képletűcsoport, ahol R5 jelentése alkilcsoport, hidroxilcsoport,alkoxicsoport vagy NR6R7 képletű csoport, ahol R6 és R7 jelentéseegymástól függetlenül hidrogénatom vagy alkilcsoport, vagy R6 és R7közül az egyik jelentése hidrogénatom vagy alkilcsoport, és a másikjelentése SO2R4 képletű csoport, ahol R8 jelentése hidrogénatom vagyalkilcsoport, vagy E jelentése szubsztituált heteroarilcsoport vagy(E-1), (E-2) vagy (E-3) képletű csoport, azzal a megszorítással, hogyha A jelentése 2-fenil-5-metil-oxazol-4-il-csoport, X jelentése (X-2)képletű csoport, Q jelentése fenilcsoport, Y és Z jelentése CH2csoport, B jelentése hidrogénatom és E jelentése CO2H csoport, akkor Djelentése pirrolilcsoporttól eltérő. A találmány kiterjed a fentivegyületeket tartalmazó gyógyszerkészítményekre és a vegyületekelőállítására. Ó
HU0401620A 2001-08-29 2002-07-15 Orális antidiabetikus hatóanyagok és eljárás előállításukra HUP0401620A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31572801P 2001-08-29 2001-08-29
PCT/IB2002/002843 WO2003018553A1 (en) 2001-08-29 2002-07-15 Oral antidiabetic agents

Publications (1)

Publication Number Publication Date
HUP0401620A2 true HUP0401620A2 (hu) 2004-11-29

Family

ID=23225787

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401620A HUP0401620A2 (hu) 2001-08-29 2002-07-15 Orális antidiabetikus hatóanyagok és eljárás előállításukra

Country Status (35)

Country Link
EP (2) EP1423363B1 (hu)
JP (1) JP2005504778A (hu)
KR (1) KR20040044515A (hu)
CN (1) CN1558897A (hu)
AP (1) AP2002002616A0 (hu)
AR (1) AR036301A1 (hu)
AT (1) ATE323674T1 (hu)
BG (1) BG108597A (hu)
BR (1) BR0212069A (hu)
CA (1) CA2458621A1 (hu)
CZ (1) CZ2004272A3 (hu)
DE (1) DE60210784T2 (hu)
EA (1) EA200400140A1 (hu)
EC (1) ECSP044999A (hu)
EE (1) EE200400075A (hu)
ES (1) ES2260456T3 (hu)
GT (1) GT200200175A (hu)
HN (1) HN2002000242A (hu)
HR (1) HRP20040164A2 (hu)
HU (1) HUP0401620A2 (hu)
IL (1) IL159886A0 (hu)
IS (1) IS7114A (hu)
MA (1) MA27135A1 (hu)
MX (1) MXPA04001968A (hu)
NO (1) NO20040881L (hu)
OA (1) OA12653A (hu)
PA (1) PA8553701A1 (hu)
PE (1) PE20030563A1 (hu)
PL (1) PL369569A1 (hu)
SK (1) SK1182004A3 (hu)
SV (1) SV2003001213A (hu)
TN (1) TNSN04038A1 (hu)
UY (1) UY27424A1 (hu)
WO (1) WO2003018553A1 (hu)
ZA (1) ZA200400374B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059907A1 (fr) * 2002-01-17 2003-07-24 Takeda Chemical Industries, Ltd. Composes heterocycliques azotes : procede de preparation et d'utilisation
PA8594401A1 (es) * 2003-02-21 2004-09-16 Pfizer Acidos carboxilicos de heteroarilo condensado como agonista del ppar
EP1620088A4 (en) * 2003-04-28 2007-08-29 Bayer Pharmaceuticals Corp ACETIC INDOLE ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS
EP1641788A1 (en) * 2003-06-27 2006-04-05 Warner-Lambert Company LLC Preparation of n2-alkylated 1,2,3-triazoles
WO2005005423A1 (en) * 2003-07-02 2005-01-20 F. Hoffmann-La Roche Ag Indolyl derivatives substituted with a thiazole ring and their use as ppar modulators
KR20130023381A (ko) * 2003-07-17 2013-03-07 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
BRPI0416238A (pt) * 2003-11-05 2007-01-02 Hoffmann La Roche compostos, processo para a sua preparação, composição farmacêutica que compreende os mesmos, uso dos compostos e métodos para o tratamento e/ou a prevenção de doenças que são moduladas por ppar(delta) e/ou agonistas ppar(alfa)
EP1689389A4 (en) 2003-12-04 2009-06-17 Nat Health Research Institutes Indole compounds
EP1694669B1 (en) * 2003-12-11 2007-04-11 Galderma Research & Development, S.N.C. Novel compounds which are modulators of the ppar-type receptors and their use in cosmetic or pharmaceutical compositions
FR2863610B1 (fr) * 2003-12-11 2006-01-20 Galderma Res & Dev NOUVEAUX COMPOSES MODULATEURS DES RECEPTEURS DE TYPE PPARs ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
JP4599395B2 (ja) * 2004-03-09 2010-12-15 エフ．ホフマン−ラ ロシュ アーゲー Ｐｐａｒ活性化剤としてのピラゾリルインドリル誘導体
US7405236B2 (en) * 2004-08-16 2008-07-29 Hoffman-La Roche Inc. Indole derivatives comprising an acetylene group
TW200724138A (en) * 2005-03-29 2007-07-01 Sk Corp Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
PL2014652T3 (pl) 2006-04-18 2015-02-27 Nippon Chemiphar Co Czynnik aktywujący receptor aktywowany przez proliferatory peroksysomów
AU2013202514B2 (en) * 2006-04-18 2015-09-17 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor delta
KR101871665B1 (ko) 2008-04-15 2018-06-27 닛뽕 케미파 가부시키가이샤 퍼옥시좀 증식제 활성화 수용체의 활성화제
FR2976942B1 (fr) * 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
FR2976943B1 (fr) 2011-06-23 2013-07-12 Metabolys Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE69828445D1 (de) * 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
AU6190299A (en) * 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use
US6274608B1 (en) * 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
US7348426B1 (en) * 1999-04-28 2008-03-25 Dr. Reddy's Laboraties Limited Substituted bicyclic heterocycles, process for their preparation and their use as antiobesity and hypocholesterolemic agents
WO2001017994A1 (en) * 1999-09-08 2001-03-15 Glaxo Group Limited Oxazole ppar antagonists

Also Published As

Publication number Publication date
JP2005504778A (ja) 2005-02-17
OA12653A (en) 2006-06-16
CZ2004272A3 (cs) 2005-02-16
SV2003001213A (es) 2003-03-18
DE60210784D1 (de) 2006-05-24
BG108597A (bg) 2005-03-31
ZA200400374B (en) 2005-03-30
CN1558897A (zh) 2004-12-29
BR0212069A (pt) 2004-07-20
AP2002002616A0 (en) 2002-09-30
ATE323674T1 (de) 2006-05-15
HRP20040164A2 (en) 2004-10-31
ES2260456T3 (es) 2006-11-01
SK1182004A3 (sk) 2005-03-04
DE60210784T2 (de) 2006-11-02
EE200400075A (et) 2004-08-16
GT200200175A (es) 2003-05-23
EA200400140A1 (ru) 2004-08-26
EP1423363A1 (en) 2004-06-02
CA2458621A1 (en) 2003-03-06
MA27135A1 (fr) 2005-01-03
EP1423363B1 (en) 2006-04-19
IL159886A0 (en) 2004-06-20
KR20040044515A (ko) 2004-05-28
UY27424A1 (es) 2003-03-31
TNSN04038A1 (fr) 2006-06-01
WO2003018553A8 (en) 2004-04-08
WO2003018553A1 (en) 2003-03-06
IS7114A (is) 2004-01-15
AR036301A1 (es) 2004-08-25
HN2002000242A (es) 2002-12-12
EP1577305A1 (en) 2005-09-21
PE20030563A1 (es) 2003-06-23
MXPA04001968A (es) 2004-06-07
NO20040881L (no) 2004-04-19
PA8553701A1 (es) 2003-07-28
PL369569A1 (en) 2005-05-02
ECSP044999A (es) 2004-04-28

Similar Documents

Publication Publication Date Title
HUP0401620A2 (hu) Orális antidiabetikus hatóanyagok és eljárás előállításukra
HUP0402309A2 (hu) Glükokináz-aktivátorként szolgáló amidszármazékok és a vegyületeket tartalmazó gyógyászati készítmények
CY1108313T1 (el) Παραγωγα της κινολινης και η χρηση τους ως προσδεματων 5-ht6
HUP0400323A2 (hu) Tirozin-kináz inhibitorok és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0001140A2 (hu) Szubsztituált pirimidinon és piridonszármazékok, továbbá ezeket tartalmazó gyógyászati készítmények
HUP0300203A2 (en) Novel cyclic amide derivatives, and pharmaceutical compositions containing same
CY1106237T1 (el) Ετepοκυκλικα παραγωγα με 5 μελη στο δακτυλιο και εφαρμογη αυτων ως παρεμποδιστων της μονοαμινο οξυδασης
HUP0001848A2 (hu) NOS gátló 6-fenil-piridil-2-amin származékok
HUP0401009A2 (hu) 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DK0652868T3 (da) Hæmmere af c-AMP-phosphodiesterase
CY1113077T1 (el) Προφαρμακα λεβοντοπα και συνθεσεις και χρησεις αυτων
DK0682033T3 (da) Hydrolyserbare og polymeriserbare silaner
HUP0300080A2 (hu) Új malonsavszármazékok, eljárás előállításukra, ezek alkalmazása Xa faktor inhibitorként és ezeket tartalmazó gyógyszerkészítmények
ES2127912T3 (es) Benzoderivados condensados.
HUP0402019A2 (hu) CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítmények
HUP0105108A2 (hu) Amidvegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0000729A2 (hu) Új amidszármazékok és ezeket tartalmazó gyógyszerkészítmények
CY1108148T1 (el) Αβερμεκτινης- και μονοσακχαριτη αβερμεκτινης παραγωγα υποκατεστημενα στην 4''- ή 4'- θεση που εχουν ζιζανιοκτονες ιδιοτητες
HUP0004588A2 (hu) Szubsztituált 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-ol-származékok, eljárás előállításukra és alkalmazásuk gyógyszerként, valamint a vegyületeket tartalmazó gyógyszerkészítmények
HUP0201357A2 (hu) Aszimmetrikus rézkomplex, előállítása, és eljárás ciklopropánkarbonsav-észter-származékok előállítására felhasználásával
DE69314911D1 (de) Cis-epoxide Derivate, verwendbar als irreversible HIV-Protease Inhibitoren und Verfahren und Zwischenprodukte zu ihrer Herstellung
HUP9902199A1 (hu) Új nitronszármazékok, ezek előállítási eljárása és ezeket tartalmazó gyógyszerkészítmények
HUP0303593A2 (hu) Biguanidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0300154A2 (en) Method for the production of spirocyclic tetronic acid derivatives
GR1000997B (el) Μεθοδος για την παρασκευη παραγωγων 8-χλωροκινολονης.